Compare WABC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WABC | TSHA |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | United States | United States |
| Employees | 627 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | WABC | TSHA |
|---|---|---|
| Price | $58.75 | $4.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $64.00 | $13.00 |
| AVG Volume (30 Days) | 171.7K | ★ 2.8M |
| Earning Date | 10-15-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 3.40 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,023.00 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $44.93 | $3.69 |
| 52 Week High | $63.61 | $7.30 |
| Indicator | WABC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 38.99 |
| Support Level | $55.80 | $4.37 |
| Resistance Level | $60.49 | $5.07 |
| Average True Range (ATR) | 1.21 | 0.24 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 0.00 | 37.78 |
Westamerica Bancorp provides a full range of banking services to individual and commercial customers in Northern and Central California through its subsidiary bank. The Bank is a California-chartered commercial bank whose deposits are insured by the Federal Deposit Insurance Corporation (the FDIC) up to applicable limits. The principal communities served are located in Northern and Central California, from Mendocino, Lake and Nevada Counties in the north to Kern County in the south. The Company's strategic focus is on the banking needs of small businesses.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.